2 results
Approved WMOCompleted
PrimaryTo evaluate confirmed ORR of Trastuzumab deruxtecan in human epidermal growth factor receptor 2- (HER2-) mutated NSCLC subjects treated at 5.4 and 6.4 mg/kg doses.Secundary- To evaluate the clinical efficacy of Trastuzumab deruxtecan at 5.4…
Approved WMORecruiting
All efficacy and safety objectives will compare enzalutamide plus leuprolide and enzalutamide monotherapyversus placebo plus leuprolide.